MIF-CD74通过ENO2互作调控滑膜巨噬细胞代谢-炎症重编程驱动骨关节炎
本研究整合小鼠滑膜时间分辨单细胞RNA测序与人OA组织空间转录组,鉴定出在OA中扩增并定位于滑膜-软骨界面的致病性CD74+巨噬细胞亚群,该亚群呈促炎非经典极化且依赖糖酵解。机制上CD74与ENO2互作,促进HIF-1α/β-catenin二聚体核转位,共激活糖酵解与炎症基因程序。髓系CD74基因敲除或药理阻断可减轻小鼠OA滑膜炎与软骨降解;滑膜靶向阳离子脂质纳米颗粒递送CD74 siRNA经关节腔注射可改善小鼠OA进展。
要点
- CD74+巨噬细胞亚群在OA滑膜中扩增,定位于滑膜-软骨界面,呈促炎且依赖糖酵解。
- CD74/ENO2/HIF-1α/β-catenin轴整合代谢重编程与炎症,驱动OA滑膜炎。
- 滑膜靶向PcLNPs递送CD74 siRNA经关节腔注射可减轻小鼠OA进展。
核心结论
- CD74/ENO2/HIF-1α/β-catenin轴是OA滑膜炎代谢重编程与炎症的关键整合轴,靶向该轴或可改变OA疾病进程。
研究设计与样本
- 研究整合小鼠滑膜时间分辨单细胞RNA测序与人OA组织空间转录组分析,并结合多组学与机制实验。
- 在小鼠OA模型中采用髓系细胞CD74基因敲除与药理阻断进行功能验证。
- 开发滑膜靶向阳离子脂质纳米颗粒(PcLNPs)递送CD74 siRNA,经关节腔注射评估体内疗效。
主要发现
- 鉴定出在OA中扩增并定位于滑膜-软骨界面的致病性CD74+巨噬细胞亚群,呈促炎非经典极化且依赖糖酵解。
- CD74与糖酵解酶ENO2互作,促进HIF-1α/β-catenin二聚体核转位,共激活糖酵解与炎症基因程序。
- 髓系CD74基因敲除或药理阻断减轻小鼠OA模型滑膜炎与软骨降解。
- 关节腔注射PcLNPs有效靶向CD74+巨噬细胞,减弱其炎症与糖酵解表型,改善小鼠OA进展。
临床怎么用
- CD74+巨噬细胞亚群及CD74/ENO2/HIF-1α/β-catenin轴可作为OA滑膜炎的潜在干预靶点。
- 滑膜靶向PcLNPs递送CD74 siRNA的关节腔给药策略为OA疾病修饰提供候选纳米治疗方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Synovitis is a central driver of osteoarthritis (OA) progression, yet the cellular and molecular mechanisms sustaining inflammatory circuits in the synovium remain incompletely understood. Through integrative analysis of time-resolved single-cell RNA sequencing in murine synovium and spatial transcriptomics of human OA tissues, we identified a pathogenic CD74+ macrophage subset that expands in OA and localizes at the synovial-cartilage interface. This subset exhibits a proinflammatory, nonclassical polarization and displays a metabolic dependency on glycolysis. Multiomics and mechanistic studies revealed that CD74 interacts with the glycolytic enzyme enolase 2 (ENO2). This interaction orchestrates a feed-forward signaling axis wherein CD74/ENO2 facilitates the nuclear translocation of hypoxia-inducible factor 1-α (HIF-1α)/β-catenin dimers, which coactivate glycolytic and inflammatory gene programs, thereby sustaining a metabolically driven inflammatory state. Genetic ablation of CD74 in myeloid cells or its pharmacological blockade mitigated synovitis and cartilage degradation in murine OA models. To translate this axis therapeutically, we developed synovium-targeted cationic lipid nanoparticles decorated with MIF-mimetic peptides (PcLNPs) for the delivery of CD74 siRNA. Intra-articular administration of PcLNPs efficiently targeted CD74+ macrophages, attenuated their inflammatory and glycolytic phenotypes, and ameliorated murine OA progression in vivo. Our findings establish the CD74/ENO2/HIF-1α/β-catenin axis as a critical integrator of metabolic reprogramming and inflammation in OA synovitis and present a potential targeted nanotherapeutic strategy for disease modification.
引用
- Peng, Yu, Wei, et al. MIF-CD74 orchestrates synovial macrophage metabolic-inflammatory reprogramming by ENO2 interaction to drive osteoarthritis pathogenesis. Sci Transl Med. 2026. PMID: 42950016. doi:10.1126/scitranslmed.adz4081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。